|Awarded On||November 16, 2016|
|Title||A novel compound targeting CD38 for the treatment of multiple myeloma|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Institution/Organization||Molecular Templates, Inc.|
|Principal Investigator/Program Director||Jason Kim|
In 2015, there were approximately 27,000 new cases of multiple myeloma diagnosed in the US making it the second most prevalent blood cancer. The five-year survival rate for multiple myeloma is 45% and the median survival is approximately 4 years. CD38 is a protein expressed on the surface of myeloma cells.
Recently, daratumumab, an antibody that specifically targets CD38, was approved for the treatment of patients with multiple myeloma. Daratumumab works primarily by binding myeloma cells and recruiting an immune response to them. Most patients’ immune system will ultimately stop responding to daratumumab allowing the disease to progress. Molecular Templates, a venture-backed biopha...